Why the study?
Does verapamil 360 mg/day reduce death and reinfarction in patients after an acute myocardial infarction?
Does verapamil 360 mg/day reduce death and reinfarction in patients after an acute myocardial infarction?
Verapamil 360 mg/day initiated in the second week after an acute myocardial infarction significantly reduces the risk of death and reinfarction.
Answers are grounded in this paper and cite their sources.
Supports verapamil 360 mg/day from week 2 post-MI to cut death and reinfarction; confirms pooled benefit in secondary prevention.
The effect of verapamil on death and reinfarction after an acute myocardial infarction was studied in two double-blind, randomized, placebo-controlled multicenter trials, the Danish Verapamil Infarction Trials I and II (DAVIT I and II). The studies demonstrated that verapamil 360 mg/day from the 2nd week after an acute myocardial infarction, prevented death and reinfarction. Meta-analyses of the results of DAVITs I and II resulted in a reduction of pooled ratios of 22% (95% confidence limits 1-37, p=0.04) for death, 21% (5-35, p=0.02) for first major events (first reinfarction or death), and 27% (6-43, p=0.02) for the first reinfarctions
No takes yet. Share an insight, caveat, or question.
Jørgen Fischer Hansen (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: